Literature DB >> 21360720

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.

Zobair M Younossi1, Maria Stepanova, Nila Rafiq, Hala Makhlouf, Zahra Younoszai, Ritambhara Agrawal, Zachary Goodman.   

Abstract

UNLABELLED: Since the initial description of nonalcoholic steatohepatitis (NASH), several sets of pathologic criteria for its diagnosis have been proposed. However, their interprotocol agreement and ability to predict long-term liver-related mortality (LRM) have not been demonstrated. In this study, we examined patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) for whom liver biopsy slides and clinical and mortality data were available. Liver biopsy samples were evaluated for a number of pathologic features and were classified according to the presence or absence of NASH by (1) the original criteria for NAFLD subtypes, (2) the nonalcoholic fatty liver disease activity score (NAS), (3) the Brunt criteria, and (4) the current study's criteria. All NASH diagnostic criteria and individual pathologic features were tested for agreement and for their independent associations with LRM, which were determined with a Cox proportional hazards model. Two hundred fifty-seven NAFLD patients with complete data were included. The diagnoses of NASH by the original NAFLD subtypes and by the current study's definition of NASH were in almost perfect agreement (κ = 0.896). However, their agreement was moderate with NAS (κ = 0.470 and κ = 0.511, respectively) and only fair to moderate with the Brunt criteria (κ = 0.365 and κ = 0.441, respectively). Furthermore, the agreement of the Brunt criteria with NAS was relatively poor (κ = 0.178). During the follow-up (median = 146 months), 31% of the patients died (9% were LRM). After we controlled for confounders, a diagnosis of NASH by the original criteria for NAFLD subtypes [adjusted hazard ratio = 9.94 (95% confidence interval = 1.28-77.08)] demonstrated the best independent association with LRM. Among the individual pathologic features, advanced fibrosis showed the best independent association with LRM [adjusted hazard ratio = 5.68 (95% confidence interval = 1.50-21.45)].
CONCLUSION: The original criteria for NAFLD subtypes and the current study's criteria for NASH were in almost perfect agreement, but their level of agreement with the NAS and Brunt criteria was lower. A diagnosis of NASH by the original criteria for NAFLD subtypes demonstrated the best predictability for LRM in NAFLD patients.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21360720     DOI: 10.1002/hep.24268

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  169 in total

1.  Smoking and Liver Disease.

Authors:  Stephanie M Rutledge; Amon Asgharpour
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-12

Review 2.  Micro RNAs in the development of non-alcoholic fatty liver disease.

Authors:  Glenn S Gerhard; Johanna K DiStefano
Journal:  World J Hepatol       Date:  2015-02-27

3.  Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Maria Stepanova; Nila Rafiq; Hala Makhlouf; Ritambhara Agrawal; Ishmeet Kaur; Zahra Younoszai; Arthur McCullough; Zachary Goodman; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2013-06-18       Impact factor: 3.199

4.  Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis.

Authors:  Lei Zhao; Maria Westerhoff; Rish K Pai; Won-Tak Choi; Zu-Hua Gao; John Hart
Journal:  Mod Pathol       Date:  2017-09-01       Impact factor: 7.842

Review 5.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

6.  Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis.

Authors:  Toshiaki Teratani; Kengo Tomita; Takahiro Suzuki; Hirotaka Furuhashi; Rie Irie; Makoto Nishikawa; Junji Yamamoto; Toshifumi Hibi; Soichiro Miura; Tohru Minamino; Yuichi Oike; Ryota Hokari; Takanori Kanai
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

Review 7.  Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy.

Authors:  Cristiane Valle Tovo; Angelo Zambam de Mattos; Gabriela Perdomo Coral; Fernanda Schild Branco; Eiji Suwa; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 8.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

Review 9.  Magnetic Resonance Elastography of Liver: Current Update.

Authors:  Safa Hoodeshenas; Meng Yin; Sudhakar Kundapur Venkatesh
Journal:  Top Magn Reson Imaging       Date:  2018-10

Review 10.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.